Melanoma Matters27 Joulu 2024

Ep 58: Best of 2024: SMR

Summary

Favorite holiday songs... perhaps unexpectedly one of our hosts faves is Christmas Card From a Hooker in Minneapolis ... guess which?

In another Best of 2024 episode of Melanoma Matters, hosts Sapna Patel and James Larkin discuss key findings from the Society for Melanoma Research (SMR) meeting. They spotlight the TIL for CNS mets study, KEYMAKER U02 Substudy 02D, IMA203, KeyVibe, and the MERLIN 001 study. They emphasize the importance of understanding patient eligibility for clinical trials and the challenges of translating trial results to real-world patient care.

Keywords

melanoma, cellular therapy, brain metastases, clinical trials, treatment efficacy, sentinel lymph node biopsy, immunotherapy, melanoma research, patient care, oncology

Takeaways

The pilot trial of life elusive cellular therapy shows feasibility and safety.

Inclusion criteria for clinical trials often exclude real-world patients.

KEYMAKER U02 Substudy 02D did not demonstrate significant activity in brain metastases.
IMA203 is a non-surgical cellular therapy trial option for patients with advanced melanoma

Adjuvant TIGIT plus PD-1 therapy is unlikely to be effective in melanoma (KeyVibe)

Gene expression tests may not reliably identify patients who can forgo sentinel lymph node biopsies (MERLIN 001).

Chapters

00:00 Festive Greetings and Holiday Tunes

02:44 TIL for CNS Mets

09:04 KEYMAKER U02: Substudy 02D

12:51 IMA203

16:48 KeyVibe

19:27 MERLIN 001

23:28 Happy Holidays!

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(87)

Ep 83: Guest Megan Othus and Time of Day Administration

James and Sapna welcome Megan Othus, Professor of Biostatistics at the Fred Hutch Cancer Center and one of the key statisticians at SWOG.Megan talks about growing up in the PNW and going East to get b...

24 Kesä 40min

Ep 82: Best of ASCO: 2026

In this episode, James & Sapna tease the size of ASCO and ESMO and number of simultaneous publications.They review the most impactful melanoma and Merkel cell carcinoma presentations from ASCO 2026, f...

13 Kesä 1h 4min

Live from ASCO 2026: a preview

James & Sapna sent a brief message from ASCO 2026 about what they are looking forward to hearing at the meeting.OptimUM-02ADAMKN-942Neoadjuvant pilot studies... and more

1 Kesä 6min

Ep 81: IGNYTE trial (RP1 + nivo)

SummaryThe conversation covers the published data from the IGNYTE study - RP1 + nivolumab: response rate and safety profile, RNA-seq analysis, and toxicity. The key takeaways include insights into cli...

13 Helmi 32min

Ep 80: 2025 Holiday Special

SummaryHappy Holidays and Festive Season Everyone! In this episode of Melanoma Matters, hosts Sapna Patel and James reflect on their "cultural" experiences over the past year, discussing movies, music...

30 Joulu 202535min

Ep 79: coBRIM, COMBI-d 5-year follow-up

SummaryIn this episode of Melanoma Matters, James awaits an invitation to a film premiere (The Penguin Lessons) and we all await a picture of him in his tuxedo! Sapna and James go on to discuss the 5-...

29 Joulu 202536min

Ep 78 TRAILER: MEK inhibitor trials

Enjoy this short trailer on MEK inhibitor monotherapy trials in melanoma

29 Joulu 20251min

Ep 78: MEK inhibitor trials (METRIC, NEMO, pimasertib)

SummarySo many shoutouts in this episode of Melanoma Matters! Sapna and James engage in a lively discussion about MEK inhibitors as monotherapy treatment. They explore the METRIC, NEMO, and pimasertib...

29 Joulu 202537min